Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical

NCT05088928 is registered in ClinicalTrials.gov with Scotmann Pharmaceuticals as lead sponsor.

NCT NCT05088928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05088928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical
Lead sponsor
Scotmann Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2022
Completion date
August 30, 2022
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19